Takeda Pharmaceutical Company Limited announced that the U.S. Food & Drug Administration (FDA) has accepted a New Drug Application (NDA) for maribavir for the treatment of CMV infection in those that are refractory with or without resistance (R/R), in solid organ transplant (SOT) or hematopoietic cell transplant (HCT) recipients.
- Read more about FDA grants priority review of maribavir for the treatment of post transplant with cytomegalovirus infection
- Log in or register to post comments
source https://www.pharmatutor.org/pharma-news/2021/fda-grants-priority-review-of-maribavir-for-the-treatment-of-post-transplant-with-cytomegalovirus-infection
No comments:
Post a Comment